Your browser doesn't support javascript.
loading
Mid-term results in the treatment of varicose veins with N-butyl cyanoacrylate.
Eroglu, Erdinc; Yasim, Alptekin; Ari, Murat; Ekerbicer, Hasan; Kocarslan, Aydemir; Kabalci, Mehmet; Acipayam, Mehmet.
  • Eroglu E; 1 Faculty of Medicine, Department of Cardiovascular Surgery, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
  • Yasim A; 1 Faculty of Medicine, Department of Cardiovascular Surgery, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
  • Ari M; 2 Department of Cardiovascular Surgery, Gaziantep State Hospital, Gaziantep, Turkey.
  • Ekerbicer H; 3 Faculty of Medicine, Department of Public Health, Sakarya University, Sakarya, Turkey.
  • Kocarslan A; 1 Faculty of Medicine, Department of Cardiovascular Surgery, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
  • Kabalci M; 4 Faculty of Medicine, Department of Cardiovascular Surgery, Kirikkale University, Kirikkale, Turkey.
  • Acipayam M; 1 Faculty of Medicine, Department of Cardiovascular Surgery, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Phlebology ; 32(10): 665-669, 2017 Dec.
Article en En | MEDLINE | ID: mdl-28669248
ABSTRACT
Aim To present mid-term results of patients with varicose veins treated with N-butyl cyanoacrylate (VariClose®), a nontumescent endovenous ablation technique. Patients and method Endovenous ablation was performed on 180 patients with saphenous vein incompetence between May and October 2014. One hundred sixty-eight subjects capable of being followed-up for 30 months were included. Patients' pre- and postoperative data were recorded. Results Procedures were performed on the great saphenous vein in 159 patients and on the small saphenous vein in nine patients. Saphenous vein diameters ranged between 5.5 mm and 14 mm. Full ablation was achieved in all patients following the procedure. No complications were encountered. Patients were monitored for 30 months. Ablation rates were 100% at the 3rd month, 98.3% at the 6th month, 96.6% at 1 year, and 94.1% at 30 months. Mean venous clinical severity score was 10.2 before procedures, decreasing to 3.9 at 3 months, 4.2 at 6 months, 2.9 at 12 months, and 2.7 at 30 months ( p = 0.000). Conclusion Due to its high success rate, absence of complications, no tumescent anesthesia requirement and high patient satisfaction, endovenous ablation with N-butyl cyanoacrylate is a good method. However, long-term follow-up results are now needed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vena Safena / Várices / Enbucrilato / Procedimientos Endovasculares Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vena Safena / Várices / Enbucrilato / Procedimientos Endovasculares Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article